Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

What is Mounjaro KwikPen and how does it work? According to Eli Lilly, the Mounjaro KwikPen is a multi-dose, single-patient-use, prefilled pen designed for once-weekly injections. It offers a more ...

CDSCO allows Lilly to launch weight-loss drug Mounjaro in pen format The KwikPen is a multi-dose, single-patient-use prefilled pen designed for once-in-a week administration ...

Eli Lilly and Company's obesity and Type 2 diabetes drug, Mounjaro, has received approval from the Indian drug control authority for its presentation in its KwikPen form. The company received approval ...

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...

Eli Lilly's obesity and Type 2 diabetes drug, Mounjaro, has gained approval from the Indian drug control authority for its KwikPen form.

According to the company, it is a multi-dose, prescription-based, single-patient-use prefilled pen designed for once-weekly administration.

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment options.

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, intensifying the race for India's booming obesity drug market.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan Skrmetti.